NSG 555
ADVANCED PRIMARY CARE II
Clinical Management Exam Review
UPDATE
50 Multiple-Choice Questions
Complete Answers with Explained Rationales
Aligned with Current Clinical Guidelines
Wilkes University | Advanced Practice Nursing
Cardiovascular • Pulmonary • Endocrine • GI • MSK • Infectious Disease
For academic study and clinical review • Verify with current institutional protocols
,NSG 555 | Clinical Management Exam Review | 2026/2027 UPDATE
How to Use This Review
This comprehensive exam review contains 50 high-yield multiple-choice questions covering the core clinical
management topics of NSG 555 – Advanced Primary Care II. Each item is followed by the correct answer and
rationales that explain the underlying pathophysiology or guideline recommendation, why the correct option is
preferred, and why the distractors are incorrect.
Topics span cardiovascular disease (HFrEF, AF, valvular lesions, aortic dissection), pulmonary medicine (COPD,
asthma, CAP, lung-cancer screening), endocrinology (diabetes, thyroid, metabolic syndrome), gastroenterology,
rheumatology/gout, infectious disease, hematology, nephrology, ophthalmology, urology, and preventive care
guidelines (USPSTF, ADA, GOLD, AHA/ACC).
Study tip: Attempt each question before reading the answer. Then carefully review the rationale—paying special
attention to the clinical decision-making points that distinguish the correct choice from plausible alternatives.
These rationales reinforce the same reasoning process used on the examination and in clinical practice.
Topic Index (Selected High-Yield Areas)
• Heart Failure with Reduced Ejection Fraction (HFrEF) & ARNI therapy — Q1
• COPD exacerbation pathogens & GOLD staging — Q2, Q17, Q42
• Chronic Venous Insufficiency vs. Peripheral Arterial Disease — Q3, Q22
• Type 2 Diabetes + ASCVD – SGLT2 inhibitor prioritization — Q4, Q36, Q50
• Asthma severity classification (NAEPP) — Q5
• Thyroid function test interpretation & subclinical hypothyroidism — Q6, Q20, Q26
• Gout flare prophylaxis when starting allopurinol — Q7
• Atrial Fibrillation ECG diagnosis & DOAC preference — Q8, Q13
• GERD first-line pharmacotherapy — Q9
• Retinal detachment & Central Retinal Artery Occlusion emergencies — Q10, Q49
• Community-acquired pneumonia outpatient treatment (ATS/IDSA) — Q11
• Iron-deficiency anemia & GI malignancy work-up — Q12, Q24
• CHA2DS2-VASc anticoagulation decisions — Q13
• Meniscal exam (McMurray) vs. ACL tests — Q14
• Aortic dissection red-flag presentation — Q15
• USPSTF lung-cancer screening criteria — Q16
• Osteoarthritis imaging & first-line therapy — Q19, Q35
• Acute cholangitis (Charcot triad) & secondary hypertension — Q38, Q39
• Testicular torsion – time-critical surgical emergency — Q46
• BPH, CKD medication safety, Lyme disease, statin monitoring — Q31, Q33, Q43, Q45
Page 2
, NSG 555 | Clinical Management Exam Review | 2026/2027 UPDATE
Question 1
A 68-year-old male with HFrEF (LVEF 35%) and hypertension is currently taking Lisinopril 20mg daily and
Carvedilol 6.25mg BID. He remains symptomatic (NYHA Class II). What is the next most appropriate
pharmacologic adjustment according to current guidelines?
A. Increase Carvedilol to 12.5mg BID
B. Add Amlodipine for better blood pressure control
C. Switch Lisinopril to Sacubitril/Valsartan
D. Initiate Digoxin to improve contractility
Answer: C
Rationale
According to the 2022 AHA/ACC/HFSA Heart Failure Guideline, patients with HFrEF who remain symptomatic on an
ACE inhibitor (or ARB) should be switched to an angiotensin receptor–neprilysin inhibitor (ARNI) such as
Sacubitril/Valsartan. ARNI therapy has been shown in the PARADIGM-HF trial to further reduce cardiovascular death
and heart-failure hospitalization compared with ACE-inhibitor therapy alone. A mandatory 36-hour washout is required
when transitioning from an ACE inhibitor to avoid the risk of angioedema. While up-titration of the beta-blocker is also
important, the guideline prioritizes the ACEI-to-ARNI switch in symptomatic patients once foundational therapy is
established. Amlodipine has no mortality benefit in HFrEF, and digoxin is reserved for selected patients with persistent
symptoms or rate-control needs.
Question 2
In a patient presenting with an acute exacerbation of COPD (AECOPD) and increased sputum purulence,
which organism is a common bacterial pathogen requiring targeted antibiotic therapy?
A. Mycoplasma pneumoniae
B. Moraxella catarrhalis
C. Legionella pneumophila
D. Staphylococcus epidermidis
Answer: B
Rationale
The three most common bacterial pathogens isolated in AECOPD are Haemophilus influenzae, Streptococcus
pneumoniae, and Moraxella catarrhalis. Increased sputum purulence is a clinical marker that strongly suggests a
bacterial etiology and supports the decision to prescribe antibiotics. Mycoplasma and Legionella are atypical organisms
more typically associated with community-acquired pneumonia rather than classic AECOPD. Staphylococcus
epidermidis is a common skin contaminant and not a respiratory pathogen in this context. Empiric antibiotic selection
(e.g., amoxicillin-clavulanate, doxycycline, or a respiratory fluoroquinolone) should cover these three typical organisms.
Page 3
ADVANCED PRIMARY CARE II
Clinical Management Exam Review
UPDATE
50 Multiple-Choice Questions
Complete Answers with Explained Rationales
Aligned with Current Clinical Guidelines
Wilkes University | Advanced Practice Nursing
Cardiovascular • Pulmonary • Endocrine • GI • MSK • Infectious Disease
For academic study and clinical review • Verify with current institutional protocols
,NSG 555 | Clinical Management Exam Review | 2026/2027 UPDATE
How to Use This Review
This comprehensive exam review contains 50 high-yield multiple-choice questions covering the core clinical
management topics of NSG 555 – Advanced Primary Care II. Each item is followed by the correct answer and
rationales that explain the underlying pathophysiology or guideline recommendation, why the correct option is
preferred, and why the distractors are incorrect.
Topics span cardiovascular disease (HFrEF, AF, valvular lesions, aortic dissection), pulmonary medicine (COPD,
asthma, CAP, lung-cancer screening), endocrinology (diabetes, thyroid, metabolic syndrome), gastroenterology,
rheumatology/gout, infectious disease, hematology, nephrology, ophthalmology, urology, and preventive care
guidelines (USPSTF, ADA, GOLD, AHA/ACC).
Study tip: Attempt each question before reading the answer. Then carefully review the rationale—paying special
attention to the clinical decision-making points that distinguish the correct choice from plausible alternatives.
These rationales reinforce the same reasoning process used on the examination and in clinical practice.
Topic Index (Selected High-Yield Areas)
• Heart Failure with Reduced Ejection Fraction (HFrEF) & ARNI therapy — Q1
• COPD exacerbation pathogens & GOLD staging — Q2, Q17, Q42
• Chronic Venous Insufficiency vs. Peripheral Arterial Disease — Q3, Q22
• Type 2 Diabetes + ASCVD – SGLT2 inhibitor prioritization — Q4, Q36, Q50
• Asthma severity classification (NAEPP) — Q5
• Thyroid function test interpretation & subclinical hypothyroidism — Q6, Q20, Q26
• Gout flare prophylaxis when starting allopurinol — Q7
• Atrial Fibrillation ECG diagnosis & DOAC preference — Q8, Q13
• GERD first-line pharmacotherapy — Q9
• Retinal detachment & Central Retinal Artery Occlusion emergencies — Q10, Q49
• Community-acquired pneumonia outpatient treatment (ATS/IDSA) — Q11
• Iron-deficiency anemia & GI malignancy work-up — Q12, Q24
• CHA2DS2-VASc anticoagulation decisions — Q13
• Meniscal exam (McMurray) vs. ACL tests — Q14
• Aortic dissection red-flag presentation — Q15
• USPSTF lung-cancer screening criteria — Q16
• Osteoarthritis imaging & first-line therapy — Q19, Q35
• Acute cholangitis (Charcot triad) & secondary hypertension — Q38, Q39
• Testicular torsion – time-critical surgical emergency — Q46
• BPH, CKD medication safety, Lyme disease, statin monitoring — Q31, Q33, Q43, Q45
Page 2
, NSG 555 | Clinical Management Exam Review | 2026/2027 UPDATE
Question 1
A 68-year-old male with HFrEF (LVEF 35%) and hypertension is currently taking Lisinopril 20mg daily and
Carvedilol 6.25mg BID. He remains symptomatic (NYHA Class II). What is the next most appropriate
pharmacologic adjustment according to current guidelines?
A. Increase Carvedilol to 12.5mg BID
B. Add Amlodipine for better blood pressure control
C. Switch Lisinopril to Sacubitril/Valsartan
D. Initiate Digoxin to improve contractility
Answer: C
Rationale
According to the 2022 AHA/ACC/HFSA Heart Failure Guideline, patients with HFrEF who remain symptomatic on an
ACE inhibitor (or ARB) should be switched to an angiotensin receptor–neprilysin inhibitor (ARNI) such as
Sacubitril/Valsartan. ARNI therapy has been shown in the PARADIGM-HF trial to further reduce cardiovascular death
and heart-failure hospitalization compared with ACE-inhibitor therapy alone. A mandatory 36-hour washout is required
when transitioning from an ACE inhibitor to avoid the risk of angioedema. While up-titration of the beta-blocker is also
important, the guideline prioritizes the ACEI-to-ARNI switch in symptomatic patients once foundational therapy is
established. Amlodipine has no mortality benefit in HFrEF, and digoxin is reserved for selected patients with persistent
symptoms or rate-control needs.
Question 2
In a patient presenting with an acute exacerbation of COPD (AECOPD) and increased sputum purulence,
which organism is a common bacterial pathogen requiring targeted antibiotic therapy?
A. Mycoplasma pneumoniae
B. Moraxella catarrhalis
C. Legionella pneumophila
D. Staphylococcus epidermidis
Answer: B
Rationale
The three most common bacterial pathogens isolated in AECOPD are Haemophilus influenzae, Streptococcus
pneumoniae, and Moraxella catarrhalis. Increased sputum purulence is a clinical marker that strongly suggests a
bacterial etiology and supports the decision to prescribe antibiotics. Mycoplasma and Legionella are atypical organisms
more typically associated with community-acquired pneumonia rather than classic AECOPD. Staphylococcus
epidermidis is a common skin contaminant and not a respiratory pathogen in this context. Empiric antibiotic selection
(e.g., amoxicillin-clavulanate, doxycycline, or a respiratory fluoroquinolone) should cover these three typical organisms.
Page 3
